Diabetes in chronic kidney disease requires practical, evidence-based care
Dr Pam Brown and Dr Colin Kenny discuss recommendations from a new international guideline on diabetes management in patients with chronic kidney disease
Type 2 diabetes: maintain glycaemic control to prevent complications
Dr Samuel Seidu and Professor Kamlesh Khunti discuss the recommendations of the Primary Care Diabetes Europe position statement on the management of type 2 diabetes
Diagnose and treat pancreatic exocrine insufficiency in diabetes
Dr Kate Millar and Professor Michael Cummings present a summary of guidance that aims to help practitioners to identify and manage pancreatic exocrine insufficiency in people with diabetes
Unintended weight loss: what’s the diagnosis?
Dr Sonya Jey explains the importance of considering and excluding sinister causes of unintentional weight loss and explores some clinical scenarios in which unintentional weight loss is a feature
Diabetes: adapt management to account for cardiovascular disease risk
Professor Peter J Grant and Professor Francesco Cosentino highlight the key recommendations from the 2019 ESC/EASD guideline on diabetes, pre-diabetes, and CVD
Test and reflect
Our multiple-choice questions (MCQs) are designed to help you test your knowledge and reflect on your learning after reading an article.
Patient scenarios: KDIGO guideline on diabetes and CKD
KDIGO guideline on chronic kidney disease and diabetes
Patient scenarios: diabetes and cardiovascular risk
Collaborative stakeholder initiative for the management of type 2 diabetes in older people
Best practice in managing co-morbidities in type 2 diabetes
Educational resources
Managing patients with type 2 diabetes—a cardiometabolic pathway for a cardiovascular risk reduction approach
This webinar has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice. Products are discussed.
View Jardiance®(empagliflozin) prescribing and adverse event reporting information
PC-GB-103199 March 2021
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103451 Date of preparation: January 2021
Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
Information intended for UK healthcare professionals only. This promotional educational webinar has been organised and funded by Takeda UK Ltd.
View prescribing information and adverse event reporting information.
C-APROM/UK/VIP/0301
Date of preparation: March 2021
Switching appropriate patients with type 2 diabetes to alogliptin from existing DPP-4 inhibitors: experience and outcomes from three Clinical Commissioning Groups and Local Health Boards
Information intended for UK healthcare professionals only. This supplement has been commissioned and funded by Takeda UK Ltd. It has been developed in partnership with Grey Bear Consultancy and published by Guidelines in Practice.
View prescribing information
C-APROM/UK/VIP/0326
Date of preparation: February 2021
Case study on Type 2 diabetes management: implementation of a DPP-4 inhibitor switch strategy across a primary care network
This advertorial has been commissioned and developed by Takeda UK Ltd. Information intended for UK healthcare professionals only.
View prescribing information.
C-APROM/UK/VIP/0298
Date of preparation: February 2021